Latest news with #CONMED
Yahoo
6 days ago
- Business
- Yahoo
Q1 Rundown: Solventum (NYSE:SOLV) Vs Other Surgical Equipment & Consumables
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at Solventum (NYSE:SOLV) and its peers. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 5 surgical equipment & consumables - diversified stocks we track reported a satisfactory Q1. As a group, revenues beat analysts' consensus estimates by 1%. In light of this news, share prices of the companies have held steady as they are up 1.6% on average since the latest earnings results. Founded in 1985, Solventum (NYSE:SOLV) develops, manufactures, and commercializes a portfolio of healthcare products and services addressing critical customer and therapeutic patient needs. Solventum reported revenues of $2.07 billion, up 2.7% year on year. This print exceeded analysts' expectations by 2.7%. Overall, it was a very strong quarter for the company with a solid beat of analysts' organic revenue estimates and a decent beat of analysts' EPS estimates. "Our first quarter fiscal year 2025 results reflect solid revenue growth across our business and the positive progress we're making as part of our 3-phased transformation," said Bryan Hanson, chief executive officer of Solventum. Solventum achieved the biggest analyst estimates beat of the whole group. The stock is up 12.6% since reporting and currently trades at $75.14. Is now the time to buy Solventum? Access our full analysis of the earnings results here, it's free. With over five decades of experience in surgical innovation since its founding in 1970, CONMED (NYSE:CNMD) develops and manufactures medical devices and equipment for surgical procedures, specializing in orthopedic and general surgery products. CONMED reported revenues of $321.3 million, up 2.9% year on year, outperforming analysts' expectations by 2.6%. The business had a very strong quarter with an impressive beat of analysts' full-year EPS guidance estimates and a solid beat of analysts' EPS estimates. CONMED pulled off the highest full-year guidance raise among its peers. The market seems happy with the results as the stock is up 15.4% since reporting. It currently trades at $56.57. Is now the time to buy CONMED? Access our full analysis of the earnings results here, it's free. With a history dating back to 1897 and a presence in virtually every hospital around the globe, Becton Dickinson (NYSE:BDX) develops and manufactures medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions and professionals worldwide. BD reported revenues of $5.27 billion, up 4.5% year on year, falling short of analysts' expectations by 1.5%. It was a slower quarter as it posted a miss of analysts' constant currency revenue estimates and a slight miss of analysts' full-year EPS guidance estimates. BD delivered the fastest revenue growth but had the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 16.4% since the results and currently trades at $173. Read our full analysis of BD's results here. With a mission critical role in preventing healthcare-associated infections, STERIS (NYSE:STE) provides infection prevention products, sterilization services, and medical equipment that help healthcare facilities and life science companies maintain sterile environments. STERIS reported revenues of $1.48 billion, up 4.3% year on year. This print was in line with analysts' expectations. Overall, it was a strong quarter as it also recorded a narrow beat of analysts' full-year EPS guidance estimates and a decent beat of analysts' EPS estimates. The stock is up 6.6% since reporting and currently trades at $242.10. Read our full, actionable report on STERIS here, it's free. With a history dating back to 1927 and a presence in over 100 countries worldwide, Zimmer Biomet (NYSE:ZBH) designs and manufactures orthopedic products including knee and hip replacements, surgical tools, and robotic technologies for joint reconstruction and spine surgeries. Zimmer Biomet reported revenues of $1.91 billion, up 1.1% year on year. This number beat analysts' expectations by 0.7%. Aside from that, it was a slower quarter as it recorded a miss of analysts' full-year EPS guidance estimates. Zimmer Biomet had the slowest revenue growth among its peers. The stock is down 10.1% since reporting and currently trades at $91.99. Read our full, actionable report on Zimmer Biomet here, it's free. The Fed's interest rate hikes throughout 2022 and 2023 have successfully cooled post-pandemic inflation, bringing it closer to the 2% target. Inflationary pressures have eased without tipping the economy into a recession, suggesting a soft landing. This stability, paired with recent rate cuts (0.5% in September 2024 and 0.25% in November 2024), fueled a strong year for the stock market in 2024. The markets surged further after Donald Trump's presidential victory in November, with major indices reaching record highs in the days following the election. Still, questions remain about the direction of economic policy, as potential tariffs and corporate tax changes add uncertainty for 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Yahoo
24-05-2025
- Business
- Yahoo
CONMED (NYSE:CNMD) Is Due To Pay A Dividend Of $0.20
CONMED Corporation (NYSE:CNMD) will pay a dividend of $0.20 on the 3rd of July. This payment means that the dividend yield will be 1.4%, which is around the industry average. We've discovered 3 warning signs about CONMED. View them for free. We aren't too impressed by dividend yields unless they can be sustained over time. However, prior to this announcement, CONMED's dividend was comfortably covered by both cash flow and earnings. This means that most of what the business earns is being used to help it grow. Looking forward, earnings per share is forecast to rise by 8.8% over the next year. Assuming the dividend continues along recent trends, we think the payout ratio could be 19% by next year, which is in a pretty sustainable range. View our latest analysis for CONMED The company has been paying a dividend for a long time, and it has been quite stable which gives us confidence in the future dividend potential. The last annual payment of $0.80 was flat on the annual payment from10 years ago. While the consistency in the dividend payments is impressive, we think the relatively slow rate of growth is less attractive. Investors who have held shares in the company for the past few years will be happy with the dividend income they have received. CONMED has impressed us by growing EPS at 27% per year over the past five years. Rapid earnings growth and a low payout ratio suggest this company has been effectively reinvesting in its business. Should that continue, this company could have a bright future. Overall, we think that this is a great income investment, and we think that maintaining the dividend this year may have been a conservative choice. Distributions are quite easily covered by earnings, which are also being converted to cash flows. Taking this all into consideration, this looks like it could be a good dividend opportunity. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. As an example, we've identified 3 warning signs for CONMED that you should be aware of before investing. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
1 Russell 2000 Stock with Solid Fundamentals and 2 to Steer Clear Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial. The high-risk, high-reward nature of the Russell 2000 makes stock selection critical, and we're here to guide you toward the right ones. Keeping that in mind, here is one Russell 2000 stock that could deliver strong gains and two that may struggle to keep up. Market Cap: $1.73 billion With over five decades of experience in surgical innovation since its founding in 1970, CONMED (NYSE:CNMD) develops and manufactures medical devices and equipment for surgical procedures, specializing in orthopedic and general surgery products. Why Do We Think Twice About CNMD? Sales trends were unexciting over the last five years as its 6.7% annual growth was below the typical healthcare company Subscale operations are evident in its revenue base of $1.32 billion, meaning it has fewer distribution channels than its larger rivals Low returns on capital reflect management's struggle to allocate funds effectively CONMED's stock price of $56.06 implies a valuation ratio of 12.5x forward P/E. Dive into our free research report to see why there are better opportunities than CNMD. Market Cap: $1.15 billion With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments. Why Are We Cautious About ANIP? Revenue base of $674.1 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 7 percentage points Push for growth has led to negative returns on capital, signaling value destruction ANI Pharmaceuticals is trading at $57.27 per share, or 8.9x forward P/E. If you're considering ANIP for your portfolio, see our FREE research report to learn more. Market Cap: $1.35 billion Originally known as Safariland, Cadre (NYSE:CDRE) specializes in manufacturing and distributing safety and survivability equipment for first responders. Why Are We Positive On CDRE? Annual revenue growth of 9.7% over the last two years beat the sector average and underscores the unique value of its offerings Projected revenue growth of 19.3% for the next 12 months is above its two-year trend, pointing to accelerating demand Earnings growth has trumped its peers over the last two years as its EPS has compounded at 19.7% annually At $33.13 per share, Cadre trades at 20.8x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21-05-2025
- Business
- Business Wire
CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors
LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. 'LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board,' said Pat Beyer, President and Chief Executive Officer, CONMED. 'I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her continued service as a Director will be extremely valuable to the company.' 'It's a privilege to take on the role of Chair of the Board,' said Ms. Council. 'I look forward to continuing to work closely with the Board, Pat, and the entire CONMED leadership team on executing the Company's long-term strategy. We are all focused on empowering healthcare providers to deliver exceptional outcomes for patients, delivering favorable returns for our stockholders, creating an engaging environment for our employees, and driving the long-term success of the business.' 'It's been an honor to serve, and to continue to serve, as a member of CONMED's Board of Directors, to have served as the Lead Independent Director from 2020 to 2024, and most recently to have served as Chair of the Board,' said Ms. Goldberg Aronson. 'This change in Board Chair reflects CONMED's commitment to refreshing our Board and Committee Chairs through periodic rotations. I'm incredibly optimistic about the future of CONMED and know the Board, under LaVerne's leadership, will help guide the Company to continued success.' About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit Forward-Looking Statements This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Yahoo
13-05-2025
- Business
- Yahoo
STERIS (STE) Q1 Earnings: What To Expect
Medical equipment and services company Steris (NYSE:STE). will be reporting earnings tomorrow after the bell. Here's what investors should know. STERIS missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $1.37 billion, up 5.6% year on year. It was a decent quarter for the company, with full-year EPS guidance in line with analysts' estimates. Is STERIS a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting STERIS's revenue to grow 3.8% year on year to $1.47 billion, slowing from the 10.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.60 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. STERIS has missed Wall Street's revenue estimates six times over the last two years. Looking at STERIS's peers in the surgical equipment & consumables - diversified segment, some have already reported their Q1 results, giving us a hint as to what we can expect. CONMED delivered year-on-year revenue growth of 2.9%, beating analysts' expectations by 2.6%, and Solventum reported revenues up 2.7%, topping estimates by 2.7%. CONMED traded up 16.9% following the results while Solventum was also up 5.2%. Read our full analysis of CONMED's results here and Solventum's results here. There has been positive sentiment among investors in the surgical equipment & consumables - diversified segment, with share prices up 4.5% on average over the last month. STERIS is up 4.1% during the same time and is heading into earnings with an average analyst price target of $251.36 (compared to the current share price of $233.10). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. Sign in to access your portfolio
